Physician profile
Per Rosenkvist
NPI 1194051169
$29,284.06
in general payments reported to CMS, 2019-2025
21 companies · $2,991 in 2025
The $2,991 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,196 · 2022: $6,788 · 2023: $7,072 · 2024: $11K · 2025: $2,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $8,184 · Consulting Fee: $4,320 · Food and Beverage: $4,173 · Travel and Lodging: $3,722 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $8,184.00 |
| Consulting Fee | $4,320.00 |
| Food and Beverage | $4,173.27 |
| Travel and Lodging | $3,722.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $18,623.57 | 2021-2025 | Giapreza |
| Teleflex LLC | $6,257.56 | 2024-2025 | Arrow |
| Shionogi INC | $846.56 | 2022-2025 | Fetroja |
| Astrazeneca Pharmaceuticals Lp | $656.85 | 2021-2024 | Andexxa |
| Abbvie INC. | $609.56 | 2021-2025 | |
| Gilead Sciences, INC. | $421.29 | 2021-2025 | Veklury |
| Alexion Pharmaceuticals, INC. | $299.70 | 2021-2023 | Ultomiris |
| Chiesi USA, INC. | $294.97 | 2022-2025 | Cleviprex, Kengreal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.08 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $238.31 | 2025 | Terlivaz |
| Edwards Lifesciences Corporation | $162.22 | 2021 | |
| Arrow International, INC. | $137.30 | 2024 | Arrow |
| Janssen Biotech, INC. | $124.34 | 2022 | |
| Solventum Corporation | $112.90 | 2024-2025 | Prevena, V.A.C. Ats, Curos |
| Ucb, INC. | $44.85 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mindray Ds USA, INC. | $43.87 | 2022 | |
| Melinta Therapeutics, LLC | $40.69 | 2022-2023 | Rezzayo, Kimyrsa, Vabomere |
| Boston Scientific Corporation | $29.84 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $17.86 | 2023 | Recarbrio, Zerbaxa, Dificid |
| Medline Industries Lp | $15.11 | 2023 | |
| Philips North America LLC | $14.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Per Rosenkvist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.